PBYI
PBYI
Company information not available. Track real-time insider trading activity, SEC Form 4 filings, and executive stock transactions.
Insider Buys
0
$0
Insider Sales
29
$3.06M
Total Volume
$3.06M
38 transactions
Net Activity
$3.06M
Net selling
Sentiment Rating
Moderate DistributionCEO Conviction Index
Liquidating / Profit Taking
Key Drivers
- •Heavy distribution: sales represent 100% of total transaction value.
- •CEO selling activity detected. Often driven by option expiration or diversification plans.
Score Methodology
The Insider Confidence Score (1-100) measures executive conviction. Starting from a neutral 50, it adjusts based on:
- +15Strong Buy Ratio: Purchases > 70% of volume (or up to -15 for heavy sales).
- +20Cluster Buying: ≥3 unique insiders buying within a 30-day window.
- +15CEO Buying: CEO committing own capital shows high conviction.
- +10CFO Buying: CFO purchasing shares shows financial alignment.
Auerbach Alan H
Pres, CEO, 10%
$842K total
Cesano Alessandra
Dir
$699K total
Senderowicz Adrian
Dir
$286K total
Moyes Jay M
Dir
$234K total
Miller Michael Patrick
Dir
$219K total
Quick Actions
PBYI has an insider buy conviction of 0%, compared to the Unknown sector buy average of 6%. PBYI ranks #464 in insider activity out of 569 tracked companies in its industry.
Over the last 90 days, corporate insiders at PBYI (PBYI) engaged in a total of 38 transactions reported via SEC Form 4 filings. Among these, 0 were open-market purchases and 29 were sales. The total volume of insider trading reached $3.06M.
The net insider activity for PBYI shows a net selling bias of $3.06M. This activity represents a 0% buy ratio, suggesting that insiders are currently bearish on the company's near-term outlook relative to recent history.
The most notable individual transaction was a Sale by Cesano Alessandra (Dir), who traded 62.1K shares valued at $567K on Sep 14, 2026.
Is Puma Biotechnology (PBYI) a Great Value Stock Right Now?
(PBYI) Risk Channels and Responsive Allocation
PBYI - Puma Biotechnology Inc Stock Price and Quote
Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why
Puma Biotechnology, Inc. 2026 Q3 - Results - Earnings Call Presentation (NASDAQ:PBYI) 2026-11-10
Puma Biotechnology (PBYI) director Miller holds 66,000 shares directly after selling 15,000.
FAQs About PBYI Insider Trading
Answers to common questions regarding corporate filings and executive sentiment for PBYI.